Aurinia Pharmaceuticals Inc. AUPH
Institutional shares held
58.6 Million
1.14M
calls
1.51M
puts
Total value of holdings
$560M
$10.9M
calls
$14.4M
puts
Market Cap
$1.36B
141,892,000
Shares Out.
Institutional ownership
41.29%
# of Institutions
208
We take great care to ensure that the data presented and summarized in this overview for Aurinia Pharmaceuticals Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AUPH
View all-
Black Rock Inc. New York, NY9.27MShares$88.5 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY8.2MShares$78.3 Million1.0% of portfolio
-
Tang Capital Management LLC San Diego, CA7.23MShares$69 Million4.52% of portfolio
-
Nea Management Company, LLC Timonium, MD3.97MShares$37.9 Million2.22% of portfolio
-
State Street Corp Boston, MA2.95MShares$28.1 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY2.41MShares$23 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.77MShares$16.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.62MShares$15.5 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.47MShares$14 Million0.0% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL1.35MShares$12.9 Million0.0% of portfolio
Latest Institutional Activity in AUPH
Top Purchases
Top Sells
About AUPH
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Insider Transactions at AUPH
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 09
2024
|
Tang Kevin C |
BUY
Open market or private purchase
|
Indirect |
500,000
+5.6%
|
$4,500,000
$9.09 P/Share
|
|
Dec 06
2024
|
Tang Kevin C |
BUY
Open market or private purchase
|
Indirect |
400,000
+4.8%
|
$3,600,000
$9.01 P/Share
|
|
Dec 05
2024
|
Tang Kevin C |
BUY
Open market or private purchase
|
Indirect |
300,000
+3.83%
|
$2,400,000
$8.91 P/Share
|
|
Nov 21
2024
|
Jill Leversage Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,135
+32.63%
|
-
|
|
Nov 21
2024
|
Karen L. Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,135
+32.85%
|
-
|
|
Nov 21
2024
|
Jeffrey Allen Bailey Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,135
+32.25%
|
-
|
|
Nov 21
2024
|
Craig A Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,631
+50.0%
|
-
|
|
Nov 21
2024
|
David R.W. Jayne Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,135
+17.68%
|
-
|
|
Nov 11
2024
|
Jeffrey Allen Bailey Director |
SELL
Open market or private sale
|
Direct |
4,557
-25.44%
|
$36,456
$8.43 P/Share
|
|
Nov 11
2024
|
Karen L. Smith Director |
SELL
Open market or private sale
|
Direct |
5,241
-29.26%
|
$41,928
$8.43 P/Share
|
|
Nov 08
2024
|
Jeffrey Allen Bailey Director |
BUY
Exercise of conversion of derivative security
|
Direct |
17,913
+50.0%
|
-
|
|
Nov 08
2024
|
Karen L. Smith Director |
BUY
Exercise of conversion of derivative security
|
Direct |
17,913
+50.0%
|
-
|
|
Aug 06
2024
|
Scott Michael Habig Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
18,249
-3.85%
|
$91,245
$5.31 P/Share
|
|
May 21
2024
|
Brinda Balakrishnan Director |
SELL
Open market or private sale
|
Direct |
520
-2.88%
|
$2,600
$5.74 P/Share
|
|
May 21
2024
|
Jill Leversage Director |
SELL
Open market or private sale
|
Direct |
5,610
-30.28%
|
$28,050
$5.74 P/Share
|
|
May 21
2024
|
David R.W. Jayne Director |
SELL
Open market or private sale
|
Direct |
4,946
-10.03%
|
$24,730
$5.74 P/Share
|
|
May 21
2024
|
Daniel Billen Director |
SELL
Open market or private sale
|
Direct |
5,252
-15.73%
|
$26,260
$5.74 P/Share
|
|
May 21
2024
|
R. Hector Mac Kay Dunn |
SELL
Open market or private sale
|
Direct |
5,630
-23.24%
|
$28,150
$5.74 P/Share
|
|
Mar 06
2024
|
Joseph M Miller Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
34,811
-6.56%
|
$174,055
$5.6 P/Share
|
|
Mar 06
2024
|
Peter Greenleaf Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
126,981
-7.7%
|
$634,905
$5.6 P/Share
|
Last 12 Months Summary
Buy / Acquisition
2.77M
Shares
From
13
Insiders
| Grant, award, or other acquisition | 1.53M shares |
|---|---|
| Open market or private purchase | 1.2M shares |
| Exercise of conversion of derivative security | 35.8K shares |
Sell / Disposition
374K
Shares
From
13
Insiders
| Open market or private sale | 374K shares |
|---|